JPS62210991A - Production of crude drug - Google Patents
Production of crude drugInfo
- Publication number
- JPS62210991A JPS62210991A JP61055838A JP5583886A JPS62210991A JP S62210991 A JPS62210991 A JP S62210991A JP 61055838 A JP61055838 A JP 61055838A JP 5583886 A JP5583886 A JP 5583886A JP S62210991 A JPS62210991 A JP S62210991A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- crude drug
- linum
- medium
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 13
- 241000208204 Linum Species 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims description 5
- 240000006240 Linum usitatissimum Species 0.000 abstract description 12
- 235000004426 flaxseed Nutrition 0.000 abstract description 11
- 235000004431 Linum usitatissimum Nutrition 0.000 abstract description 10
- 230000004069 differentiation Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 230000034303 cell budding Effects 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract 3
- 239000002609 medium Substances 0.000 description 16
- 206010020649 Hyperkeratosis Diseases 0.000 description 15
- 241000411851 herbal medicine Species 0.000 description 9
- 239000000306 component Substances 0.000 description 8
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 229930192334 Auxin Natural products 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000002363 auxin Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 etc. Chemical compound 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035784 germination Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006870 ms-medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 2
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 2
- 239000004062 cytokinin Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 2
- 229960001669 kinetin Drugs 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000020197 coconut milk Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
+8)産業上の利用分野
本発明はアマ<Linum )属の植物体の有する生薬
成分を総合的に活用するため、アマ属植物を組織培養し
、得たカルスを収穫して生薬として利用する方法に関す
る。[Detailed description of the invention] +8) Industrial application field The present invention is directed to tissue culturing plants of the genus Linum and harvesting the resulting callus in order to comprehensively utilize the medicinal components contained in plants of the genus Linum. and how to use it as a herbal medicine.
(b)従来の技術
アマ(Linum usitatissimum )及
びその種子の亜麻仁は、古来生薬として用いられてきた
。即ち根は補虚、活血薬に、茎や葉は鎮痛、止血薬に、
また亜麻仁は皮膚のかゆみ止めや養毛剤、胃腸薬。(b) Prior Art Linum (Linum usitatissimum) and its seeds, flaxseed, have been used as herbal medicines since ancient times. In other words, the roots are used as a supplement and blood stimulant, and the stems and leaves are used as analgesics and hemostasis.
Flaxseed is also an anti-itching agent for the skin, a hair tonic, and a gastrointestinal medicine.
解毒鎮痛薬として用いられてきた(保育社「原色日本薬
用植物図鑑」昭和58年版)。It has been used as a detoxifying analgesic (Yakusha's "Illustrated Encyclopedia of Japanese Medicinal Plants" 1981 edition).
また亜麻仁のリン脂質は血清コレステロール値を下げる
作用が強く、動脈硬化症の予防にも有効である(特開昭
60−126224号)。Furthermore, the phospholipids in flaxseed have a strong effect of lowering serum cholesterol levels and are also effective in preventing arteriosclerosis (Japanese Patent Application Laid-open No. 126224/1983).
さらに亜麻仁から得られるアマニ油は、我が国では塗料
などの工業用に用いられているが、欧米ではリルン酸を
主な栄養源とする健康食品に使用されている。Furthermore, linseed oil obtained from flaxseed is used in industrial applications such as paints in Japan, while in Europe and the United States it is used in health foods whose main nutritional source is lilunic acid.
このように、アマは種子、茎9葉、根のすべてを健康食
品ないし生薬として活用でき、植物体全部を総合的に活
用することも可能である。In this way, the seeds, stems, leaves, and roots of flax can all be used as health foods or herbal medicines, and it is also possible to use the entire plant body comprehensively.
(C)発明が解決しようとする問題点
しかるに現在アマはわが国ではほとんど栽培されず、ア
マニ油を採取するため種子が専ら輸入されている状況で
ある。しかし、輸入種子の亜麻仁から得る生薬は限られ
た工程からしか得られず、また根や生の茎1葉も入手し
に(い。(C) Problems to be Solved by the Invention However, at present, flax is hardly cultivated in Japan, and the seeds are exclusively imported to extract flaxseed oil. However, the herbal medicine obtained from imported flaxseed seeds can only be obtained through a limited number of processes, and the roots and raw stem leaves are also difficult to obtain.
本発明はMi織培養によって必要とする成分を含む培養
物を工場生産の規模で得る方法を提供せんとするもので
、この発明によればアマの任意の生薬成分を任意の時期
に得ることができる。即ち、根の有効成分、茎9葉の有
効成分或いは亜麻仁の有効成分を別々にでも総合的にで
も任意に得ることが可能となる。The present invention aims to provide a method for obtaining a culture containing necessary components on a factory production scale by Mi weave culture.According to this invention, any crude medicinal component of flax can be obtained at any time. can. That is, it becomes possible to obtain the active ingredients of the root, the active ingredients of the stems and leaves, or the active ingredients of the flaxseed separately or collectively.
なお、植物の組織培養によって生薬を作る方法としては
チョウセンニンジン(特開昭48−31917号)、サ
イコ(特公昭56−52557号)など多くの発明があ
るが、アマのカルスを培養し、その収穫物から生薬を製
造する方法は未だ知られてい□ない。In addition, there are many inventions such as ginseng (Japanese Patent Publication No. 31917/1983) and Saiko (Japanese Patent Publication No. 52557/1983) as methods for producing crude drugs by culturing plant tissue. There is still no known method for producing crude drugs from harvested products.
また、油脂生産植物を組織培養してその培養物からトコ
フェロールを製造する技術が大豆(特開昭59−154
998号)、ベニバナ(特開昭60−149393号)
などで知られているが、アマ属の植物の組織培養による
脂質成分の製造法は未だ知られていない。In addition, a technology for producing tocopherols from tissue culture of oil-producing plants was developed by soybean (Japanese Patent Application Laid-Open No. 59-154).
998), Safflower (Japanese Unexamined Patent Publication No. 149393/1983)
However, there is still no known method for producing lipid components by tissue culture of plants of the genus Linum.
(d1問題点を解決するための手段
即ち本発明は、アマ属植物を人工培地により組織培養し
、培養物を得ることを特徴とする生薬の製造法である。(Means for solving the problem d1, that is, the present invention is a method for producing crude drugs, which is characterized by tissue-cultivating plants of the genus Linum in an artificial medium to obtain a cultured product.
本発明に用いるアマ属の植物としてはLinumusi
tatissimum、 Linum angusti
foliumなどが挙げられるが、これらに限定される
ものではない。The plants of the genus Linum used in the present invention include Linumusi
tatissimum, Linum angusti
Examples include, but are not limited to, folium.
ここでは通常、生薬として用いるアマを例として以下詳
細に説明する。Here, flax, which is usually used as a herbal medicine, will be explained in detail below as an example.
アマ属のカルスを誘導するには一般的な公知の手法が適
用できる。即ち、アマの芽ばえや成長の旺盛な植物体の
組織切片、例えば葉、茎、茎頂。General known methods can be applied to induce callus of the genus Linus. That is, tissue sections of budding or actively growing flax plants, such as leaves, stems, and shoot tips.
根、花の組織切片や種子の胚のいずれを培養してもよい
が、最も培養しやすい芽ばえの葉、茎から組織切片を採
ると作業性が良い。Tissue sections of roots, flowers, or seed embryos may be cultured, but it is easier to collect tissue sections from leaves and stems of sprouts, which are easiest to culture.
カルスの培養に用いる培地は一般的な無機塩類を基本と
した人工培地またはそれらの改変培地、例えばムラシゲ
・スクーグ(MS)の培地、ホワイトの培地、ヘラ−の
培地、リンスマイヤー・スクーグ(L S)の培地、エ
ッチの培地、ハイポネソクス培地などのいずれでもよく
、またこれらの培地に限定することなく公知のどの培地
を使用することもでき、それらの基本組成を適宜改変し
てもよい。培地には、ビタミン類としてサイアミン塩酸
塩、ニコチン酸、ピリドキシン塩酸塩、イノシトール、
パントテン酸塩、ビオチンなど、糖としてグルコース、
蔗糖、ソルビトールなど、アミノ酸としてグリシン、ア
スパラギン、グルタミン 。The medium used for culturing callus is a general artificial medium based on inorganic salts or a modified medium thereof, such as Murashige-Skoog (MS) medium, White's medium, Heller's medium, Linsmeyer-Skoog (LS). ), Etchi's medium, Hyponesox medium, etc., and any known medium can be used without being limited to these media, and the basic composition thereof may be modified as appropriate. The medium contains vitamins such as thiamine hydrochloride, nicotinic acid, pyridoxine hydrochloride, inositol,
Pantothenate, biotin, etc., glucose as a sugar,
Amino acids such as sucrose and sorbitol, as well as glycine, asparagine, and glutamine.
などの有機物を適宜添加し得る。また、植物ホルモンと
してオーキシン類すなわち2.4−D、インドール酢酸
、インドール酪酸、ナフタレン酢酸などやサイトカイニ
ン類即ちカイネチン、ベンジルアデニン、ゼアチンなど
を適宜組み合わせて用い、ココナツミルク、イーストエ
キス、モルトエキス、ペプトン、カゼイン分解物、バナ
ナ汁など天然抽出物も適宜加え得る。これらの培地は液
体培地でも寒天を加え固体培地でもよい。Organic substances such as the following may be added as appropriate. In addition, as plant hormones, auxins such as 2.4-D, indoleacetic acid, indolebutyric acid, naphthaleneacetic acid, etc., and cytokinins such as kinetin, benzyladenine, zeatin, etc. are used in appropriate combinations, and coconut milk, yeast extract, malt extract, peptone , casein decomposition products, banana juice, and other natural extracts may be added as appropriate. These media may be liquid media or solid media with agar added.
本発明における培養条件として温度は15〜30℃、p
H3,5〜8.5.暗または明条件で静置または振とう
培養のいずれも採用し得る。明条件は天然光でも人工光
でもよい。植継ぎは培養物の成長に合わせて1〜6週間
毎に行い、適宜分割する。The culture conditions in the present invention include temperatures of 15 to 30°C, p.
H3,5-8.5. Either static or shaking culture in dark or light conditions may be employed. The lighting conditions may be natural light or artificial light. Transplanting is performed every 1 to 6 weeks according to the growth of the culture, and the culture is divided as appropriate.
十分増殖させた培養物は分化誘導培地に移して分化を促
進する。即ち、オーキシンの濃度を低下されカイネチン
を増加させたり、或いは植物成長ホルモンを除去したり
、塩濃度を低下させて、発根または発芽させ或いは胚状
体を形成させる。Sufficiently grown cultures are transferred to differentiation-inducing medium to promote differentiation. That is, the concentration of auxin is decreased and kinetin is increased, or the plant growth hormone is removed, or the salt concentration is decreased to cause rooting or germination or to form embryonic bodies.
MLv!A培養によって生薬成分を製造jvる際、カル
スが未分化で急速増殖期にあると、この時期のカルスに
含まれる生薬成分は希薄で、原種物体における含有有効
成分より低濃度である。しかし、カルスを分化誘導する
と有効成分が増加し、培養方法を工夫すると原種物体に
おけるよりも高濃度となる。本発明はアマ属植物のカル
スを分化誘導培地によって培養し、有効成分を高めて収
獲することが好ましく、有効脂質やその他の全成分を総
合的に得たいときには胚状体(不定胚)、葉、茎の成分
を多く得たいときには不定芽、根の成分を多く得たいと
きには不定根を夫々生ぜしめて収獲する。MLv! When producing crude drug ingredients by A culture, if the callus is undifferentiated and in a rapid growth phase, the crude drug ingredients contained in the callus at this stage are dilute and have a lower concentration than the active ingredients contained in the original material. However, when the callus is induced to differentiate, the active ingredient increases, and if the culture method is devised, the concentration becomes higher than that in the original material. In the present invention, it is preferable to culture the callus of plants of the genus Linum in a differentiation-inducing medium and harvest the active ingredients while increasing the amount of active ingredients. If you want to get a lot of stem ingredients, you can produce adventitious buds, and if you want to get a lot of root ingredients, you can produce adventitious roots.
(81実施例
実施例1
a、カルス誘専
アマニ種子を一夜流水洗浄後70%エチルアルコール液
に短時間浸漬したのち、5%次亜塩素酸ナトリウム液に
20分間浸漬して滅菌し、滅菌水で洗い、この操作をも
う1度繰り返したのち、滅菌水で十分洗浄し、滅菌した
1%寒天液を固めた培養ビン上に滅菌種子を置床し、2
5℃4日間で発芽させ、更に5日間昼明所、夜暗所の条
件を与えて芽ばえ(2〜3cm)を得、これを無菌的に
0゜5〜1cffIの組織片とし、25℃暗所でMS培
地(所定無機塩類の他、イノシトール100.サイアミ
ン塩酸塩0.1.ニコチン酸0.5.ピリドキシン塩酸
0.5.クエン酸150各m g / j! 、蔗1!
30g/lを添加後pH6に調節し、寒天9g/lを加
え、2.4−Dlppm、ベンジルアデニン0゜2pp
mを添加したもの)に置床した。10日間でカルス化が
観察され、1力月後には10〜15mmの大きさに成長
した。カルスを切離し、3週間毎に植継ぎ、2力月後に
は生育の旺盛な急速成長期のカルスを得た。(81 Examples Example 1 a. Callus-inducing flaxseed seeds were washed with running water overnight, immersed for a short time in 70% ethyl alcohol solution, then sterilized by immersion in 5% sodium hypochlorite solution for 20 minutes, and then soaked in sterile water. After repeating this operation once more, wash thoroughly with sterilized water, place the sterilized seeds on a culture bottle filled with sterilized 1% agar solution, and
Germination was carried out for 4 days at 5°C, and germination was continued for 5 days under conditions of daylight and nighttime darkness to obtain sprouts (2-3 cm), which were aseptically cut into tissue pieces of 0°5-1cffI and incubated in the dark at 25°C. By the way, MS medium (in addition to specified inorganic salts, inositol 100, thiamine hydrochloride 0.1, nicotinic acid 0.5, pyridoxine hydrochloride 0.5, citric acid 150 mg/j! each, 1!
After adding 30g/l, adjust the pH to 6, add 9g/l of agar, 2.4-Dlppm, 0°2ppm of benzyladenine.
(added with m). Callus formation was observed in 10 days, and the size grew to 10 to 15 mm after 1 month. The callus was separated and transplanted every 3 weeks, and after 2 months, a callus in the rapid growth period with vigorous growth was obtained.
b1分化誘導
このカルスを5〜lQmmに分割し、濃度を1/2に下
げたMS培地に置床し、明培養して不定芽を得た。一方
1/2濃度のMS培地からオーキシンを除去した液体培
地で3週間毎に継代し、明培養することにより胚状体を
得た。更に、急速成長期のカルスを1/2濃度のMS(
オーキシンとしてナフタレン酢酸o、sppm、サイト
カイニンとしてベンジルアデニン0.1ppm)寒天培
地で3週間暗培養したのち、1 / 298度のMS脱
ホルモン液体培地で3週間毎に継代して暗培養した結果
、発根カルスを得た。Induction of b1 differentiation This callus was divided into 5-1Q mm pieces, plated on MS medium with a concentration reduced to 1/2, and cultured in the light to obtain adventitious buds. On the other hand, embryoids were obtained by subculturing every 3 weeks in a liquid medium in which auxin was removed from a 1/2 concentration MS medium and culturing in the light. Furthermore, the callus in the rapid growth stage was treated with 1/2 concentration of MS (
Naphthalene acetic acid o, sppm as auxin, benzyladenine as cytokinin 0.1 ppm) After 3 weeks of dark culture on agar medium, subcultured in MS dehormone liquid medium at 1/298 degrees every 3 weeks and dark culture. Rooted callus was obtained.
C0生薬効果
すで得た不定芽、胚状体、不定根の各カルスを収穫し、
培地成分を十分洗い流したのち、その生薬効果を比較し
、表−1の結果を得た。C0 herbal medicine effect Harvest each callus of adventitious buds, embryonic bodies, and adventitious roots,
After thoroughly washing away the medium components, the effects of the herbal medicines were compared, and the results shown in Table 1 were obtained.
* Duke法、各5回の平均値、数値は止血するまで
の時間
ジュースは濾過し、濾液をガーゼに緩く含ませ、穿刺後
30秒間軽く穿刺部に当てたのち、取り除いて測定、蒸
留水も同様。*Duke method, the average value of each 5 times, the value is the time until bleeding stops. Filter the juice, loosely soak the filtrate in gauze, apply it lightly to the puncture site for 30 seconds after puncturing, remove it and measure. Distilled water is also used. Same.
d、抽出成分 すで得た胚状体のリン脂質を表−2に示す。d. Extracted components Table 2 shows the phospholipids of the embryos obtained above.
表−2胚状体からの溶剤抽出リン脂質”* ヘキサン抽
出、アセトン不溶部
PC:フォスファチジルコリン
PE:フォスファチジルエタノールアミンPI:フォス
ファチジルイノシトール
表−1,−2から培養物の成分はアマ植物の生薬成分と
ほぼ同等であることがわかる。Table 2: Solvent extraction of phospholipids from embryoid bodies* Hexane extraction, acetone insoluble portion PC: Phosphatidylcholine PE: Phosphatidylethanolamine PI: Phosphatidylinositol Components of culture from Tables 1 and 2 It can be seen that it is almost equivalent to the medicinal components of flax plants.
(f)発明の効果
本発明によればこれまで製造が困難であったアマの生薬
及びその成分を工場生産の規模で任意の時期に得ること
ができるとともに、人為的にアマの必要部位の生薬成分
が任意に得られる。(f) Effects of the invention According to the present invention, it is possible to obtain flax herbal medicines and their components, which have been difficult to produce up to now, at any time on a factory production scale, and also to artificially produce the herbal medicines in the necessary parts of flax. Ingredients are optionally available.
Claims (3)
培養し、培養物を得ることを特徴とする生薬の製造法。(1) A method for producing crude drugs, which comprises tissue culturing a plant of the genus Linum in an artificial medium to obtain a culture.
1)項記載の製造法。(2) Claim No. 3 (2) Using a culture that has been induced to differentiate
The manufacturing method described in section 1).
範囲第(1)項記載の製造法。(3) The manufacturing method according to claim (1), which involves extracting and concentrating crude drug components from a culture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61055838A JPH0640828B2 (en) | 1986-03-12 | 1986-03-12 | Crude drug manufacturing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61055838A JPH0640828B2 (en) | 1986-03-12 | 1986-03-12 | Crude drug manufacturing method |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62210991A true JPS62210991A (en) | 1987-09-17 |
JPH0640828B2 JPH0640828B2 (en) | 1994-06-01 |
Family
ID=13010134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61055838A Expired - Lifetime JPH0640828B2 (en) | 1986-03-12 | 1986-03-12 | Crude drug manufacturing method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0640828B2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4831917A (en) * | 1971-08-27 | 1973-04-26 | ||
JPS5652557A (en) * | 1979-10-02 | 1981-05-11 | Aisan Ind Co Ltd | Air fuel ratio controller for carburetor |
-
1986
- 1986-03-12 JP JP61055838A patent/JPH0640828B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4831917A (en) * | 1971-08-27 | 1973-04-26 | ||
JPS5652557A (en) * | 1979-10-02 | 1981-05-11 | Aisan Ind Co Ltd | Air fuel ratio controller for carburetor |
Also Published As
Publication number | Publication date |
---|---|
JPH0640828B2 (en) | 1994-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pradhan et al. | Efficient regeneration of plants from shoot tip explants of Dendrobium densiflorum Lindl., a medicinal orchid | |
CN113179951B (en) | Rapid breeding method for tissue culture seedlings of Pandanum amazonicum | |
CN113133455B (en) | Pollen polysaccharide extract and application thereof in promoting plant growth | |
Yadav et al. | Micropropagation of Spilanthes acmella Murr.–An important medicinal plant | |
US7402433B2 (en) | Method of in-vitro micropropagation of Piper longum plants | |
CN106472317B (en) | The method of the isolated culture adventive bud evoked plant regeneration of Juglans mandshurica | |
Danial et al. | Rapid protocol of Aloe vera in vitro propagation. | |
Anburaj et al. | In vitro regeneration of Cleome viscosa–an important medicinal herb | |
Bhatia et al. | Development of a rapid method for micropropagation of a new pineapple [Ananas comosus (l.) Murr.] clone,'Yeppoon gold' | |
Alam et al. | In vitro regeneration of Paederia foetida: a widely used medicinal vine in Bangladesh. | |
KR100927314B1 (en) | The cultivation method of tomatos having the high content of calcium and the excellent value of commodities | |
Khalafalla et al. | Establishment of in vitro fast-growing normal root culture of Vernonia amygdalina-a potent African medicinal plant | |
Khan et al. | Establishment of in vitro regeneration protocol for Adhatoda vasica Nees | |
CN107466850B (en) | Blueberry plantation and its seedling fast breeding method | |
EP1418800A1 (en) | Methods and cuttings for mass propagation of plant parasites | |
JPS62210991A (en) | Production of crude drug | |
US20060015963A1 (en) | Commercially viable process for in-vitro mass culture of Chlorophytum borivilianum | |
JP3715689B2 (en) | Mass propagation of Gmelina trees using tissue culture | |
CN107347650B (en) | Tissue culture propagation method for rhodiola sacra | |
CN109662031B (en) | Tissue culture rooting method for Gynura divaricata | |
CN107223570A (en) | A kind of method for accelerating induction epipremnum aureum to sprout | |
CN113661922B (en) | Plant extract, preparation method thereof and application of plant extract as plant growth regulator | |
KR101810412B1 (en) | Method for Culturing Adventitious Roots of Pseudolarix Amabilis in Media Containing Extracts of Brown Rices through Ultrasonic Treatment | |
KR20190025237A (en) | Method for vegetative propagation of Chaenomeles sinensis using somatic embryo induction and plant regeneration | |
EP0442537B1 (en) | A mental disease therapeutic agent |